CareersPipelineCollaboration RareInnovation SVGOMG The best SVG optimizer and minifier Open SVG Paste markup Demo Contribute SVGOMG provides you several options to clean and compress your SVG files. Clean up, remove, merge, minify. Upload or copy the source of your SVG to get started! 947 bytes → 267 bytes 28.19% Finance peopleAdvance treatment Skip to main contentSkip to navigationSkip to search
HNSA   ( ,  %) SEK
Quotes are delayed 15 minutes

Some non-regulatory announcements are only available in English. All announcements required under applicable law, regulation or code are available in English and Swedish.

2025

7 Aug 2025, 07:00 | Regulatory
Notice to Extraordinary General Meeting in Hansa Biopharma AB (publ)
1 Aug 2025, 21:15 | Regulatory
Hansa Biopharma announces supportive data from treatment with imlifidase prior to the administration of gene therapy for Duchenne muscular dystrophy
29 Jul 2025, 18:00
Hansa Biopharma announces key executive appointments to support continued growth
17 Jul 2025, 07:00 | Regulatory
Hansa Biopharma Reports Second Quarter and Interim January-June 2025 Financial Results

· Hansa secures directed cash share issue of approximately 232 MSEK/US $24.3M and restructures NovaQuest debt.
· As compared to prior year Q2 IDEFIRIX product sales increased 76%.
8 Jul 2025, 08:00
Hansa Biopharma appoints Dr Richard Philipson as Chief Medical Officer
3 Jul 2025, 08:00
Hansa Biopharma to host Q2 2025 interim results conference call
30 Jun 2025, 08:00
Hansa Biopharma presents positive outcomes of five-year follow-up study of imlifidase in kidney transplantation at ESOT Congress 2025 in London
30 Jun 2025, 07:00 | Regulatory
Hansa Biopharma: Increase in number of shares and votes
Load more

E-mail

Sign up to receive updates on the latest company news and filings

Choose type

I consent to Hansa Biopharma handling my personal data. See our Privacy Policy for information about how we handle personal data.

Thank you. You will get an e-mail message to activate your subscription.